A phase I multi-center, open-label, dose escalation clinical trial of BGB-283 is designed to assess the safety, tolerability and pharmacokinetic properties of BGB-283 as a single agent

Trial Profile

A phase I multi-center, open-label, dose escalation clinical trial of BGB-283 is designed to assess the safety, tolerability and pharmacokinetic properties of BGB-283 as a single agent

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs BGB 283 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Mar 2017 Data will be presented at the 2017 American Association for Cancer Research Annual Meeting, and the company expects a decision in the first quarter of 2017 from its partner Merck KGaA on its continuation option to develop and commercialize BGB-283 outside China after Mercks review of this data, according to a BeiGene, Ltd. media release.
    • 13 Oct 2015 New trial record
    • 12 Oct 2015 Status changed from not yet recruiting to recruiting according to a BeiGene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top